Citations

Clear

6273 citation(s) found for "To, Andrew".

Diagnosis of Fungal Infections. A Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline
Haydour, Qusay, Hage, Chadi A. , Carmona, Eva M. , Epelbaum, Oleg , Evans, Scott E. , Gabe, Luke M., Knox, Kenneth S. , Wengenack, Nancy L. , Murad, M. Hassan , Carmona, Eva M , Murad, M Hassan , Kolls, Jay K. , Prokop, Larry J. , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | June 20, 2019 | Volume: 16 | Issue: 9 | Pages: 1179-1188

10.1513/annalsats.201811-766oc | PMID 31219341 Get It

Abstract Rationale Prompt diagnosis of invasive fungal infections is important because of the associated morbidity and mortality; however, diagnosis is challenging because of the nonspecific symptoms and radiographic findings. Objectives To conduct a systematic review and meta-analysis of studies that evaluated the diagnostic accuracy of serum and bronchoalveolar lavage (BAL) galactomannan (GM) and serum or BAL polymerase chain reaction (PCR) in patients with suspected invasive aspergillosis (IA), β-d-glucan in critically ill patients at risk for candidiasis or candidemia, and serology testing and antigen detection in patients with endemic mycoses (histoplasmosis, blastomycosis, and coccidioidomycosis). Methods Studies were selected and appraised by pairs of reviewers. Bivariate random effects meta-analysis was used to generate pooled sensitivity, specificity, and diagnostic likelihood ratios. Results Serum GM in patients with impaired immunity suspected of having IA had sensitivity of 0.71 (95% confidence interval [CI], 0.64–0.78) and specificity of 0.89 (95% CI, 0.84–0.92). A cutoff of 1 optical density index yielded optimal sensitivity and specificity. BAL GM in patients with impaired immunity suspected of having IA had sensitivity of 0.84 (95% CI, 0.73–0.91) and specificity of 0.88 (95% CI, 0.81–0.91). Serum or whole-blood PCR in immunocompromised patients with suspected IA had sensitivity of 0.81 (95% CI, 0.73–0.86) and specificity of 0.79 (95% CI, 0.68–0.86). BAL PCR in patients at high risk for IA had high sensitivity of 0.90 (95% CI, 0.77–0.96) and specificity of 0.96 (95% CI, 0.93–0.98) for diagnosing IA. β-d-glucan assay in patients in the intensive care unit at risk for invasive candidiasis or candidemia had sensitivity of 0.81 (95% CI, 0.74–0.86) and specificity of 0.60 (95% CI, 0.49–0.71). Data on diagnostic accuracy of antigen detection and serology testing for endemic mycoses were limited and heterogeneous (varied according to test, patient immunity, and suspected endemic disease). Conclusions The diagnosis of invasive fungal infections remains a challenge. Various serum and BAL markers can aid in diagnosis. This evidence supports the development of clinical practice recommendations by the American Thoracic Society.
The American Board of Anesthesiology’s Standardized Oral Examination for Initial Board Certification
Harman, Ann E., Keegan, Mark T. , Dainer, Rupa J., McLoughlin, Thomas M, Fahy, Brenda G. , Macario, Alex, Sun, Huaping , Warner, David O. , Patterson, Andrew J., Rathmell, James P.

Mayo Clinic

Anesthesia & Analgesia | June 20, 2019 | Volume: 129 | Issue: 5 | Pages: 1394-1400

10.1213/ane.0000000000004263 | PMID 31219924 Get It

The American Board of Anesthesiology (ABA) has been administering an oral examination as part of its initial certification process since 1939. Among the 24 member boards of the American Board of Medical Specialties, 13 other boards also require passing an oral examination for physicians to become certified in their specialties. However, the methods used to develop, administer, and score these examinations have not been published. The purpose of this report is to describe the history and evolution of the anesthesiology Standardized Oral Examination, its current examination development and administration, the psychometric model and scoring, physician examiner training and auditing, and validity evidence. The many-facet Rasch model is the analytic method used to convert examiner ratings into scaled scores for candidates and takes into account how difficult grader examiners are and the difficulty of the examination tasks. Validity evidence of the oral examination includes that it measures aspects of clinical performance not accounted for by written certifying examinations, and that passing the oral examination is associated with a decreased risk of subsequent license actions against the anesthesiologist. Explaining the details of the Standardized Oral Examination provides transparency about this component of initial certification in anesthesiology.
Lower Back Injuries in National Collegiate Athletic Association Football Players: A 5-Season Epidemiological Study
Makovicka, Justin L. , Patel, Karan A. , Deckey, David G. , Chung, Andrew S. , Hydrick, Thomas C. , Gulbrandsen, Matthew T. , Hartigan, David E. , Hassebrock, Jeffrey D. , Patel, Karan , Chung, Andrew , Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 18, 2019 | Volume: 7 | Issue: 6 | Pages: No page available

10.1177/2325967119852625 | PMID 31245431 Get It

Background: Low back injuries are common in collegiate football players and can frequently lead to persistent pain, reinjuries, and time lost from participation. Purpose: To describe the epidemiology of back injuries in National Collegiate Athletic Association (NCAA) football players during the 2009/2010 through 2013/2014 academic years utilizing the NCAA Injury Surveillance Program (ISP) database. Study Design: Descriptive epidemiology study. Methods: A convenience sample of NCAA varsity football teams was utilized to determine the rates and patterns of back injuries as well as to generate national injury estimates. The rates and distribution of back injuries were identified within the context of mechanism of injury, injury chronicity, and time lost from sport. Injury rates were calculated as the number of injuries divided by the total number of athlete-exposures (AEs). Incidence rate ratios were calculated to compare the rates of injury between season, event type, mechanism of injury, injury chronicity, and time lost from sport. Results: Nationally, there were 267 low back injuries reported in the database. These were used to estimate 7076 back injuries over the 5-year period, approximately 82% of which were new injuries. The injuries occurred at a rate of 2.70 per 10,000 AEs. Overall, injuries were 3.12 times more likely to occur in competitions than in practices. Athletes were 4.67 times more likely to sustain a back injury during the preseason compared with the postseason but were 1.41 times more likely to sustain a low back injury during the preseason compared with the regular season. Both contact and noncontact were reported equally as the mechanism of injury (37.8% and 38.3%, respectively), and unspecified low back pain was the most common injury (64.2%). Only 1.6% of patients required surgery for their injury, and the majority of athletes (59.6%) returned to play within 24 hours. Conclusion: There was a relatively high rate of lumbar back injuries at the collegiate level (2.70/10,000 AEs), the majority of which were new injuries. About 18% of reported injuries were reinjuries. Although very few required surgery, a careful examination and work-up should be conducted to evaluate each injury. Regimented physical therapy and reconditioning programs are recommended to avert reinjuries.
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility
Pardini, Barbara , Corrado, Alda, Berndt, Sonja I. , Brenner, Hermann , Caan, Bette J. , Casey, Graham , Chang‐Claude, Jenny , Gala, Manish , Gallinger, Steven , Haile, Robert W. , Harrison, Tabitha A. , Hayes, Richard B. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jenkins, Mark A. , Lindor, Noralane M. , Nan, Hongmei , Slattery, Martha L. , Vodičková, Ludmila, Vodička, Pavel , Gemignani, Federica , Peters, Ulrike , Naccarati, Alessio , Hoffmeister, Michael , Slattery, Martha L , Jenkins, Mark A , Haile, Robert W , Harrison, Tabitha A , Brenner, Hermann , Hayes, Richard B , Nan, Hongmei , Vodicka, Pavel , Caan, Bette J , Paolicchi, Elisa , Cugliari, Giovanni , Bezieau, Stéphane , Bien, Stephanie A. , Campbell, Peter T. , Chan, Andrew T. , Cotterchio, Michelle , Hopper, John L. , Marchand, Loı̈c Le , Lin, Yi , Newcomb, Polly A. , Ogino, Shuji , Potter, John D. , Schoen, Robert E. , White, Emily E. , Vymetalkova, Veronika Polakova , Landi, Stefano

Mayo Clinic

International Journal of Cancer | June 18, 2019 | Volume: 146 | Issue: 2 | Pages: 363-372

10.1002/ijc.32516 | PMID 31209889 Get It

Interindividual differences in DNA repair systems may play a role in modulating the individual risk of developing colorectal cancer. To better ascertain the role of DNA repair gene polymorphisms on colon and rectal cancer risk individually, we evaluated 15,419 single nucleotide polymorphisms (SNPs) within 185 DNA repair genes using GWAS data from the Colon Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), which included 8,178 colon cancer, 2,936 rectum cancer cases and 14,659 controls. Rs1800734 (in MLH1 gene) was associated with colon cancer risk (p‐value = 3.5 × 10−6) and rs2189517 (in RAD51B) with rectal cancer risk (p‐value = 5.7 × 10−6). The results had statistical significance close to the Bonferroni corrected p‐value of 5.8 × 10−6. Ninety‐four SNPs were significantly associated with colorectal cancer risk after Binomial Sequential Goodness of Fit (BSGoF) procedure and confirmed the relevance of DNA mismatch repair (MMR) and homologous recombination pathways for colon and rectum cancer, respectively. Defects in MMR genes are known to be crucial for familial form of colorectal cancer but our findings suggest that specific genetic variations in MLH1 are important also in the individual predisposition to sporadic colon cancer. Other SNPs associated with the risk of colon cancer (e.g., rs16906252 in MGMT) were found to affect mRNA expression levels in colon transverse and therefore working as possible cis‐eQTL suggesting possible mechanisms of carcinogenesis.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Advani, Ranjana H. , Bartlett, Nancy L. , Chang, Julie , Christian, Beth , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Khan, Nadia , Krivacic, Susan, LaCasce, Ann S. , Nademanee, Auayporn, Rabinovitch, Rachel , Reddy, Nishitha , Roberts, Kenneth B. , Smith, Stephen D. , Swinnen, Lode J., Dwyer, Mary A., Sundar, Hema, Bartlett, Nancy L , Advani, Ranjana H , Khan, Nadia , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Caimi, Paolo F. , Chavez, Julio C , Habermann, Thomas M. , Harris, Nancy L. , Kelsey, Chris R. , Mehta, Amitkumar , Reid, Erin G , Snyder, Erin Dunn , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 650-661

10.6004/jnccn.2019.0029 | PMID 31200358 Get It

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY
Prior, Thomas W., Marcucci, Guido , Jones, Daniel , Krauter, J, Heuser, Michael , Geyer, Susan M. , Klisovic, Rebecca B. , Brandwein, Joseph , Witte, Theo M. de, Niederweiser, Dietger, Appelbaum, Frederick R. , Tallman, Martin S. , Schlenk, Richard F. , Chen, Yixin , Tiecke, Eva, Ehninger, Gerhard , Döhner, Konstanze , Stone, Richard M. , Bloomfield, Clara D. , Voso, Maria Teresa , Larson, Richard A. , Lavorgna, Serena , Nomdedéu, Josep , Wei, Andrew H. , Sierra, Jorge , Sanz, Miguel Á. , Jansen, Joop H. , Medeiros, Bruno C. , Ganser, Arnold , Amadori, Sergio , Cheng, Yuan , Du, L., Thiede, Christian , Döhner, Hartmut , Lococo, Filippo

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 79-80

10.1097/01.hs9.0000559236.73191.39 Get It

Background:Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3‐TKD), induce constitutive tyrosine phosphorylation, and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3‐TKD in AML is not well established. In the phase 3 RATIFY trial [CALGB 10603/Alliance; NCT00651261; Stone et al. N Engl J Med. 2017] midostaurin, in combination with standard chemotherapy, improved survival outcomes across all three FLT3 stratification subgroups (ITD high allelic ratio (AR) [≥ 0.7], ITD low AR [< 0.7] and TKD) vs placebo.Aims:Here, a post hoc analysis was used to establish the efficacy of midostaurin in patients (pts) in the RATIFY trial stratified by FLT3‐TKD AR and NPM1 mutational status.Methods:In RATIFY, newly diagnosed pts with AML 18–60 years (y) old were randomly assigned to receive midostaurin or placebo together with standard induction and consolidation therapy followed by twelve 28‐day cycles of maintenance therapy with midostaurin or placebo. FLT3‐TKD mutation was detected by PCR and capillary electrophoresis at nine reference laboratories. The FLT3‐TKD AR was calculated as the ratio between the areas under the curve of mutant to wild‐type allele. Pts were categorized as NPM1 mutated (mut) or NPM1 wild‐type (WT) using PCR. Efficacy outcomes included complete remission (CR), overall survival (OS), event‐free survival (EFS) and disease‐free survival (DFS). EFS and DFS analyses were performed considering CR within a 60‐day window. P values presented were not adjusted for multiplicity.Results:Of 163 FLT3‐TKD pts, 134 with available NPM1 data had consented for exploratory analysis and were included in this study. Overall, 58.9% of pts had NPM1‐mut, 47.8% were male and the median age was 49 y (range: 19.3–59.9 y). The median white blood cell (WBC) count was higher in pts with NPM1‐mut than in pts with NPM1‐WT (34.1 vs 15.5 × 109 /L). The median FLT3‐TKD AR was 0.4 (range: 0–2.7). Overall CR rate (regardless of NPM1 genotype) was 64% for midostaurin and 56% for placebo in FLT3‐TKD pts. Pts with FLT3‐TKD AR ≥ 0.4 treated with midostaurin showed a trend towards improved OS and reduced cumulative incidence of relapse (CIR) (Figure). In FLT3‐TKD AR ≥ 0.4 pts, the presence of a NPM1 mutation had a significant prognostic effect for all endpoints consistently with hazard ratios (HRs) around 0.50 or lower. Regardless of treatment OS, EFS, and DFS estimates at 3 y were 73% vs 52%, 48% vs 25%, and 74% vs 47%, respectively, for the 45 pts with FLT3‐TKD/NPM1‐mut vs the 25 pts with FLT3‐TKD/NPM1‐WT. It should be noted that the number of pts in each subgroup was small. Multivariate analyses in these FLT3‐TKD pts revealed that NPM1 genotype was an independent prognostic factor for OS and EFS (2‐sided P < 0.05), whereas study drug, age, sex, TKD AR, WBC at baseline and stem cell transplantation (SCT) (no/yes) did not reach this level of significance in the Cox model.Summary/Conclusion:This post hoc analysis of the subset of FLT3‐TKD pts in the RATIFY trial showed the high prognostic value of NPM1 mutational status. Midostaurin showed an overall benefit in the FLT3‐TKD pts for OS, EFS, CR and DFS, with the impact of treatment on outcome for NPM1‐mut pts being greatest in those with higher FLT3‐TKD allelic burden. U10CA180821, U10CA180882, U24CA196171, U10CA180861; Novartis; htt∗∗∗ps://acknowledgments.alliancefound.orgimage
PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Kumar, Emil , Korfi, Koorosh , Leukam, Michael , Ansell, Stephen M. , Scott, J S, Rallis, Kathrine S , Clear, Andrew , Calaminici, Maria , Wang, J., Smith, Sonali M. , Novak, Anne J. , Bewicke‐Copley, Findlay , Witzig, Thomas E. , Scott, J., Efeyan, Alejo , Okosun, Jessica , Fitzgibbon, Jude

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 209

10.1097/01.hs9.0000560152.86937.ed Get It

Background:With an expanding array of novel treatment options in follicular lymphoma (FL), we largely lack effective biomarkers to predict response in this molecularly heterogeneous disease. Activating mutations focused on components of the nutrient‐sensing arm of the mTORC1 pathway (RRAGC, ATP6V1B2, ATP6AP1), are particularly enriched in FL, occurring in ∼30% of cases. Meanwhile, clinical mTOR inhibitors (mTORi) have shown some promise, with response rates of 50–60% in relapsed/refractory FL.Aims:We therefore sought to determine whether gene mutation status ‐ particularly in genes regulating the mTOR pathway – may represent biomarkers of mTORi‐response in FL.Methods:We retrospectively analyzed pre‐treatment tumor samples from relapsed/refractory FL patients treated on two phase II clinical trials with single agent mTOR inhibitors, everolimus (NCT00436618) or temsirolimus (NCT00290472), with well characterized clinical outcomes. In total, 21 patients had available biopsies, consisting of 15 everolimus‐ and 6 temsirolimus‐treated cases.Tumor DNA extracted from formalin fixed paraffin embedded (FFPE) tissue was subjected to targeted sequencing using a 22 gene panel comprising genes recurrently mutated in FL, and PI3K/AKT/mTOR pathway genes mutated in germinal center lymphomas. Libraries were prepared using capture‐based target enrichment (Nonacus), and sequenced on the NextSeq550 (Illumina) with a mean coverage depth of x700. A stringent bioinformatic pipeline was adopted with variants called with VarScan2, and a 10% variant allele frequency (VAF) threshold was employed to filter out sequencing artefacts due to the FFPE material. 100% (15/15) of a selection of variants were validated by Sanger sequencing. Staining for pS6 was undertaken on tissue slides to examine downstream mTOR activation by immunohistochemistry.Results:Overall response rate (CR and PR) was 48% (10/21). Mutational analysis showed no significant association between clinical response and mTORC1‐pathway mutations (mut) taken individually or collectively; although, absolute numbers of mutations in these genes were low, including RRAGC (responder: 0/10 mut vs non‐responder: 1/11 mut), ATP6AP1 (responder: 1/10 vs non‐responder: 1/11), and ATP6V1B2 (responder: 1/10 vs non‐responder 3/11). Notably, no difference in pS6 staining was seen between responders and non‐responders.However, we found mutations in the epigenetic regulator CREBBP to be enriched in the responder group (100% (10/10) responders vs 54.5% (6/11) non‐responders, p = 0.04). This effect was more pronounced when considering only mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP, with HAT mutations seen in 100% (10/10) responders, and 27.3% (3/11) non‐responders (p = 0.001).Summary/Conclusion:Mutations in the mTOR pathway did not predict for response to mTOR inhibition in our study. The enrichment of CREBBP mutations in responders, and particularly those affecting the catalytic HAT domain, points to CREBBP as a potential biomarker of response which warrants validation in trials of drugs modulating the PI3K/AKT/mTOR axis. More broadly our data may lend support to a distinct clinical and biological behavior of CREBBP HAT domain‐mutant disease that also warrants further evaluation. Taken together, our findings highlight the potential opportunities afforded by undertaking correlative studies, and underlines the need to incorporate prospective biomarker discovery into clinical trials in order to help focus future therapeutic strategies more rationally.
PF514 LOSS OF 18Q22.1‐Q23 IS SIGNIFICANTLY ASSOCIATED WITH GCB‐DLBCL AND FAILURE TO ACHIEVE EFS24
Wenzl, Kerstin , Hartert, Keenan T. , Sarangi, Vivekananda , Ansell, Stephen M. , Novak, Anne J. , Manske, Michelle K. , Krull, Jordan E. , Greipp, Patricia T. , Maurer, Matthew J. , Feldman, Andrew L. , Cerhan, James R.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 210

10.1097/01.hs9.0000560156.86937.f8 Get It

Background:Recent large next generation sequencing studies have redefined the genomic landscape of diffuse large B‐cell lymphoma (DLBCL). While many of the more common genetic variants, primarily mutations, have been biologically characterized, little is known about newly emerging genetic aberrations. In particular, somatic copy number alterations remain poorly studied due to the large genomic regions they cover and the number of genes involved. This, in combination with lack of remission or early relapse in a portion of DLBCL, opens new opportunities to explore yet unidentified genetic contributions to lymphomagenesis.Aims:The goal of this study was to identify variants associated with failure to achieve event free survival at 24 months (EFS24) and define their biologic significance in DLBCL.Methods:Newly diagnosed DLBCL treated with standard immunochemotherapy were included in this study (n = 246). Copy number data was generated by using the molecular inversion probe OncoScan™ FFPE Assay Kit (Affymetrix, Santa Clara, CA, USA). OncoScan OSCHP files were analyzed using Nexus Copy Number 9.0 software (Biodiscovery, El Segundo, USA). Data interpretation and copy number calling was done using the human reference genome GRCh37/hg19. Files were analyzed using the Nexus FASST2‐Segmentation algorithm, which is based on a Hidden Markov Model approach for calling genetic events. For functional analysis, SOCS6 was overexpressed and studied in GCB‐DLBCL cell lines.Results:Upon review of genomic copy number data from DLBCL cases (n = 246), loss of 18q22.1‐q23 was a significant event in our cohort (p = 0.018), is found in 11% (n = 27) of DLBCL, and is enriched in germinal center DLBCL (GCB‐DLBCL) patients (18/107, 17%, p < 0.05) compared to activated B‐cell (ABC)/non‐GCB DLBCL patients (1/93, 1%). Furthermore, GCB‐DLBCL patients with a loss of 18q22.1‐q23 were significantly more likely to fail EFS24 (50%, p < 0.05) compared to GCB‐DLBCL patients without the loss (29%). Genes located at 18q22.1‐q23 include, TMX3, DOK6 and SOCS6. SOCS family proteins have been shown to play an important role in tumor biology, although little is known about SOCS6. SOCS6 gene expression is downregulated in a variety of solid tumors and is hypermethylated in some hematological malignancies. RNASeq data from DLBCL suggest variable expression across tumors. Using a panel of GCB cell lines we found that SOCS6 expression was low to negative, and publically available cell line data suggests this region is hypermethylated. Expression of SOCS6 was higher in a panel of mantle cell lymphoma and ABC‐DLBCL cell lines and this again correlated with their cell line methylation data, where no hypermethylation was found in those cell lines. Together, this data suggests that downregulation of SOCS6 through genomic loss or hypermethylation may have biologic importance. To explore the role of SOCS6, we restored expression in GCB cell lines and immuno‐fluorescence staining suggest localization to the nucleus and cytoplasm, as previously reported in other cell types. Studies to explore the role of SOCS6 in cytokine signaling and STAT family protein regulation are ongoing.Summary/Conclusion:Using genome copy number data from 246 DLBCL, we have found that loss of 18q22.1‐q23 (p = 0.018) is associated with GCB‐DLBCL and failure to achieve EFS24. Furthermore, we have identified that SOCS6 may have clinical and biologic significance in GCB‐DLBCL.
PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
Spencer, Andrew , Lentzsch, Suzanne , Spicka, I., Lauri, Birgitta, Lee, J.‐J., Nooka, A., Munder, Markus , Lee, C., Barreto, Wolney, Min, Chang‐Ki , Chanan‐Khan, A.A., Horvath, Noemi , Capra, Marcelo , Ovilla, Roberto, Jo, Jin-Hyeong, Shin, Ho‐Jin , Sonneveld, Pieter , Soong, David, Casneuf, Tineke, Ukropec, Jon, Qi, Ming , Mateos, M.‐V., Weisel, Katja C , Avet‐Loiseau, Hervé , Mark, Tomer M , Spicka, I., Masszi, Tamás , Levin, Mark-David , Bosi, Alberto , Hungria, Vânia , Cavo, Michèle , Quach, Hang , Corradini, Paolo , Beksaç, Meral , Chiu, C., Amin, H., Qi, M.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 251

10.1097/01.hs9.0000560672.85259.7d Get It

Background:Patients (pts) with multiple myeloma associated with high cytogenetic risk abnormalities have poor outcomes. In CASTOR, D‐Vd prolonged progression‐free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited a manageable safety profile in pts with RRMM. We conducted a subgroup analysis of D‐Vd vs Vd in CASTOR, based on cytogenetic risk.Aims:The purpose of this analysis was to determine the efficacy and safety of D‐Vd in CASTOR based on cytogenetic risk status.Methods:Eligible pts received ≥1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next‐generation sequencing (NGS) and fluorescence in situ hybridization (FISH)/karyotype testing. High‐risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)‐risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 10–5) was assessed via NGS using clonoSEQ® assay V2.0.Results:In CASTOR (D‐Vd, n = 251; Vd, n = 247), high‐risk was confirmed in 26.7% and 25.9% of pts in the D‐Vd and Vd groups, respectively. At a median follow up of 40.0 months (mo), D‐Vd prolonged PFS vs Vd in pts with high‐ (median 13.4 vs 7.2 mo; HR, 0.40 [95% CI, 0.24–0.65]; P = 0.0002) or std‐risk (median 18.4 vs 6.8 mo; HR, 0.28 [95% CI, 0.20–0.37]; P <0.0001). Higher ORR was seen with D‐Vd vs Vd (high risk: 84.8% vs 60.0%; P = 0.0226; std risk: 85.4% vs 65.0%; P <0.0001), including deep responses of ≥CR (high risk: 33.3% vs 8.3%; std risk: 29.9% vs 10.2%) and ≥VGPR (high risk: 65.2% vs 35.0%; P = 0.0049; std risk: 64.3% vs 28.0%; P <0.0001). Higher rates of MRD negativity (high risk: 17.9% vs 0%; P = 0.0003; std risk: 13.3% vs 2.4%; P = 0.0003), and sustained MRD negativity for ≥6 mo (high risk: 16.4% vs 0%; P = 0.0006; std risk: 6.1% vs 1.8%; P = 0.0859) and ≥12 mo (high risk: 7.5% vs 0%; P = 0.0581; std risk: 1.8% vs 0%; P = 0.2477) were seen with D‐Vd vs Vd. D‐Vd significantly prolonged PFS vs Vd in pts with one prior line of therapy only (high risk: median 20.1 vs 8.4 mo; HR, 0.30 [95% CI, 0.14–0.64]; P = 0.0012; std risk: median 32.6 vs 7.9 mo; HR, 0.18 [95% CI, 0.11–0.29]; P <0.0001; Figure). Additionally, D‐Vd significantly prolonged PFS2 (high risk: median 27.9 vs 18.6 mo; HR, 0.59 [95% CI, 0.37–0.94]; P = 0.0258; std risk: median 40.1 vs 21.6 mo; HR, 0.43 [95% CI, 0.32–0.59]; P <0.0001) regardless of cytogenetic risk status.Additional data including safety analyses will be presented.Summary/Conclusion:Adding daratumumab to Vd demonstrates significant efficacy in pts with high‐risk RRMM including PFS2. Among high‐risk RRMM pts, MRD negativity was only achieved with D‐Vd. These findings support use of D‐Vd for high‐risk RRMM. NCT02136134image
PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Belch, Andrew R. , White, Darrell , Cheung, M., Chen, C., Shustik, Chaim, Song, Kevin , Tosikyan, Axel, Kotey, Stanley, Brown, Diane , Srinivasan, S. , Bahlis, Nizar Jacques , Cheung, M., Dispenzieri, Angela , Anderson, Kenneth C. , Brown, D., Robinson, S., Facon, Thierry T.F.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 962

10.1097/01.hs9.0000567032.31064.27 Get It

Background:The pivotal FIRST trial, the largest study conducted in transplant‐ineligible (TNE) patients (pts) with newly diagnosed multiple myeloma (NDMM), examined lenalidomide plus low‐dose dexamethasone until disease progression (Rd continuous), Rd for 18 cycles (Rd18), and melphalan, prednisone, and thalidomide (MPT). The study, conducted in 18 countries in Europe, North America, and Asia Pacific, demonstrated that Rd continuous significantly improved progression‐free survival (PFS) vs MPT (median 26.0 vs 21.9 mos; HR, 0.69; 95% CI, 0.59‐0.79; P < .00001). PFS was similarly extended for Rd continuous vs Rd18 (median 21.0 mos; HR, 0.70; 95% CI, 0.60‐0.81). Furthermore, median overall survival (OS) was significantly longer with Rd continuous vs MPT (median 59.1 vs 49.1 mos; HR, 0.78; 95% CI, 0.67‐0.92; P = .0023). These results support the use of frontline oral, alkylator‐free continuous therapy for TNE NDMM pts and established Rd continuous as a standard of care as reflected by clinical guidelines in Canada, the US, and Europe.Aims:To report outcomes in the subset of patients from Canada and the US.MethodsPts with TNE NDMM were randomized 1:1:1 to Rd continuous (with lenalidomide given on days 1‐21 of 28‐day cycles until disease progression), Rd18 (with lenalidomide given on days 1‐21 of eighteen 28‐day cycles), or MPT (twelve 42‐day cycles). Rd18 and MPT were both 72 weeks in duration. Stratification factors included country and Rd continuous vs MPT was the primary comparison. The primary endpoint was PFS and secondary endpoints included OS, time to next therapy (TTNT) and safety. Time from randomization to second progression or death (PFS2) was an exploratory analysis. Response assessment used for PFS and PFS2 analysis was determined by investigators based on International Myeloma Working Group criteria. Data is presented as of the January 21, 2016 cutoff used for the final OS analysis.Results:A total of 312 pts from Canada (n = 252) and the US (n = 60) were enrolled (104 in each arm). Consistent with results from the intent‐to‐treat (ITT) analysis, the Canada/US subgroup also demonstrated a significant improvement in PFS with Rd continuous vs MPT (median 29.3 vs 20.2 mos; HR, 0.69; 95% CI, 0.49‐0.97; P = .03326) and an improvement vs Rd18 (median 21.9 mos; HR, 0.72; 95% CI, 0.51‐1.02; Table). Median OS was 56.9 vs 46.8 mos for Rd continuous vs MPT (HR, 0.77; 95% CI, 0.53‐1.11; P = .15346). Median PFS2 was longer for Rd continuous vs MPT (median 39.3 vs 35.1 mos; HR, 0.69; 95% CI 0.50‐0.95) as was TTNT (median 39.1 vs 24.6 mos; HR, 0.54; 95% CI, 0.37‐0.78). Additional details, including safety data, will be presented at the meeting.Summary/Conclusion:In the Canada/US subpopulation of pts from FIRST, Rd continuous extended median PFS by 9 mos vs MPT and > 7 mos vs Rd18. Rd continuous also delayed median TTNT > 14 mos and resulted in a longer PFS2 vs MPT, suggesting that the benefit from frontline Rd continuous is maintained at relapse. These results are consistent with that from the ITT population confirming the advantage of Rd continuous vs MPT in the Canada/US subgroup and supporting the role of Rd continuous as a standard of care for TNE pts with NDMM. The efficacy observed with Rd continuous raises the question on the role of immunostimulatory effects by the immunomodulatory agents in NDMM.image